Previous 10 | Next 10 |
The stock markets are experiencing a phase of volatility and uncertainty. Inflation fears and a potential tech bubble burst could precipitate a deep sell-off in the near-term. However, experts say that inflationary headwinds will abate by year’s end. In this scenario, we think it best ...
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, announced that management will be presenting at the following investor conferences: SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 8:00 a.m. EST Cowen Annual Health Ca...
The following slide deck was published by Ironwood Pharmaceuticals, Inc. in conjunction with their 2020 Q4 earnings call. For further details see: Ironwood Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation
Ironwood Pharmaceuticals, Inc. (IRWD) Q4 2020 Earnings Conference Call February 17, 2021 08:30 A.M. ET Company Participants Meredith Kaya - VP, IR and Corporate Communications Mark Mallon - CEO Thomas McCourt - President Gina Consylman - SVP and CFO Michael Shetzline - CMO, SVP and Head of Dr...
Image source: The Motley Fool. Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) Q4 2020 Earnings Call Feb 17, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Ironwood Pharmaceuticals Inc (IRWD) Q4 2020 Earnings Call Tran...
Ironwood Pharmaceuticals (IRWD) shares rise nearly 3% during premarket trading after the company posted fourth-quarter results that beat Wall Street estimates, as the company benefitted from higher sales for its bowel disorder treatment Linzess in the United States.Linzess brou...
– LINZESS ® (linaclotide) 2020 U.S. net sales of $931 million, up 10% year-over-year; Ironwood expects 2021 U.S. LINZESS net sales growth of 3 to 5% – – 2020 total revenue of $390 million, driven primarily by $369 million in U.S. LINZESS col...
Ironwood Pharmaceuticals (NASDAQ:IRWD) is scheduled to announce Q4 earnings results on Wednesday, February 17th, before market open.The consensus EPS Estimate is $0.29 (-3.3% Y/Y) and the consensus Revenue Estimate is $107.84M (-14.6% Y/Y).Over the last 2 years, IRWD has beaten EPS estimates ...
The odds of Ironwood Pharmaceuticals (IRWD) getting acquired may be higher after yesterday's announcement that CEO Mark Mallon will be leaving soon, according to Gordon Haskett.Ironwood has been targeted by activist Sarissa Capital in the past and the activist got a seat on the company's boar...
Ironwood Pharma (IRWD) announced that Mark Mallon plans to step down as its chief executive officer and a member of the company's Board effective March 12, 2021.The company has named Thomas McCourt, its president, as interim CEO upon Mallon’s exit.Ironwood plan...
News, Short Squeeze, Breakout and More Instantly...
Ironwood Pharmaceuticals Inc. Company Name:
IRWD Stock Symbol:
NASDAQ Market:
Ironwood Pharmaceuticals Inc. Website:
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its second quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of I...
2024-05-22 07:30:10 ET Wells Fargo analyst issues OVERWEIGHT recommendation for IRWD on May 22, 2024 05:13AM ET. The previous analyst recommendation was Overweight. IRWD was trading at $6.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...